Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Billie M. York"'
Autor:
Young Han Park, Billie M. York, John T. Slattery, Brenda W. Griffin, Philip R. Mayer, Ronnie Barker, Gary W. Williams, Mark T. DuPriest
Publikováno v:
Pharmaceutical Research. 10:593-597
The pharmacokinetics of AL03152 (RS) and its enantiomers, AL03802 (R) and AL03803 (S), were studied in the Sprague–Dawley rat following intravenous bolus administration. The enantiomers had differing pharmacokinetic profiles, while the racemic comp
Autor:
Billie M. York, D Barratt, Brenda W. Griffin, Young Han Park, R Barker, K Brazzell, Philip R. Mayer, Mark T. DuPriest
Publikováno v:
Xenobiotica. 22:543-550
1. Six potent aldose reductase inhibitors (ARI), three spirohydantoin (I to III) and three spirosuccinimide (IV to VI) compounds, showed similar IC50 activities in vitro for the inhibition of rat lens aldose reductase, but their ED50 values in diabet
Publikováno v:
British Journal of Clinical Pharmacology. 32:221-227
1. The metabolism of the aldose reductase inhibitor, ALO1567, was studied in man. The major biotransformation pathway was aromatic hydroxylation followed by glucuronide conjugation. 2. Hydroxylation occurred at several positions on the fluorene ring.
Autor:
Billie M. York, John C. Wahl, Phil Mayer, Alan L. Robin, Mark J. Vocci, James Sutton, Cheryl Enger, Adrienne Graves
Publikováno v:
Scopus-Elsevier
We performed a prospective, double-masked, placebo-controlled, six-period, cross-over study in which normal subjects were randomly assigned to treatment and compared three different formulations of apraclonidine hydrochloride (the present commerciall
Publikováno v:
The Effects of Aging and Environment on Vision ISBN: 9781461366744
Studies of the role of aldose reductase in sugar cataractogenesis have been aided by the synthesis and characterization of inhibitors of this enzyme which can prevent lens opacification in galactosemic or diabetic rats1,2. The anti-cataract activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7440bcb0b3f82ca960929fac9e1267b9
https://doi.org/10.1007/978-1-4615-3758-8_10
https://doi.org/10.1007/978-1-4615-3758-8_10
Publikováno v:
Experimental Eye Research. 46:517-530
Depletion of lens glutathione (GSH) occurs quickly and drastically following induction of diabetes or galactosemia in rats as well as in lens culture. The explanation for this dramatic loss of GSH has been investigated by many laboratories but the so
Autor:
Billie M. York, Donald A. Levin
Publikováno v:
Biochemical Systematics and Ecology. 6:61-76
The toxicity of alkaloids was sought in relation to the geography of alkaloid-bearing plants. Relative toxicity was inferred from the structure of the compounds, which exhibit regular structure-activity relationships. The toxicity of alkaloids from t
Publikováno v:
Journal of Pharmaceutical Sciences. 77:591-595
Two selective high-performance liquid chromatographic (HPLC) methods have been developed for the quantitative determination of spiro-(2-fluoro-9H-fluorene-9,4′-imidazolidine)-2′,5′-dione (AL01567; 1 ) in plasma and urine, with an assay sensitiv
Publikováno v:
Journal of ocular pharmacology. 5(3)
Normal eight month old beagle dogs were fed a diet of 30% galactose for a period of two weeks. One group of dogs was untreated while three other groups were orally dosed with 0.25, 1.0, and 5.0 mg/kg of the aldose reductase inhibitor (ARI), AL01576.
Publikováno v:
Metabolism: clinical and experimental. 36(5)
Two new potent aldose reductase inhibitors, AL-1567 (DL-spiro(2-fluoro-9H-fluoren-9,4'-imidazolidine)-2',5'-dione) and AL-1576 (spiro-(2,7-difluoro-9H-fluoren-9,4'-imidazolidine)2',5'-dione), have been characterized with respect to in vitro activity